Vaccination Liberation - Information | |||
Legal: | Science: | Misc: | Searches: |
---|---|---|---|
Exemptions State_Chapter/ Resource_Contacts Avoid_Vaccinations Activism LegalNews |
Introduction Basic_Facts Package Inserts Ingredients of Vaccines Q_and_A Artificially Sweetened Times |
Membership Books Videos Tapes 100+ Anti-Vax links Vax_Cartoons Breaking News Planned_Events |
KeyWord_Index Index/Link_Pages Search_Our_Site Home_Page Index_Page Smallpox Alert! |
FROM THE IRISH EXAMINERAnother source: An analysis by Eleanor McBean written in her book, Vaccination Condemned, "It has been said that the 1918 flu epidemic killed 20,000,000 people throughout the world. But, actually, the doctors killed them with their crude and deadly treatments and drugs. This is a harsh accusation but it is nevertheless true, judging by the success of the drugless doctors in comparison with that of the medical doctors." See the rest of this article at: [Archived on VacLib.org] THE FLU: 1918 AND NOW http://www.nomorefakenews.com/archives/archiveview.php?key=1851
|
Full Text: Oxford University Press
[Abstract only] Archived at PubMed
MAJOR ARTICLE
Oculo-respiratory Syndrome: A New Influenza VaccineAssociated Adverse Event?Danuta M. Skowronski,1 Barbara Strauss,1,4 Gaston De Serres,5 Diane MacDonald,1 Stephen A. Marion,2 Monika Naus,1 David M. Patrick,1 and Perry Kendall3
1University of British Columbia Centre for Disease Control and 2Department of Health Care and Epidemiology, University of British Columbia, Vancouver, and 3Office of the Provincial Health Officer, Ministry of Health Planning, Victoria, British Columbia; 4Health Canada, Population and Public Health Branch, Field Epidemiology Training Program, Ottawa, Ontario; and 5Institut National de Santé Publique de Québec, Quebec, CanadaDuring the 2000-2001 influenza immunization campaign in Canada, a new adverse event, oculo-respiratory syndrome (ORS), was noted in association with administration of vaccine supplied by one manufacturer. The original case definition for ORS specified bilateral conjunctivitis, facial edema, or respiratory symptoms beginning 24 h after influenza vaccination and resolving within 48 h after onset. To characterize the spectrum,https://pubmed.ncbi.nlm.nih.gov/12627354/ severity, and impact of ORS, we contacted persons who had reported any influenza vaccineassociated adverse event in British Columbia, Canada, during the 2000 2001 vaccination campaign. With use of a standardized telephone interview, we collected information from 609 (79%) of 769 eligible persons. Thirteen percent of ORS-affected persons reported onset 2 h after vaccination, 27% experienced symptoms for >48 h, and 42% considered the symptoms to be severe. The surveillance case definition for ORS for 2001-2002 was revised to include onset 24 h after vaccination, with no restriction on duration. ORS should be incorporated into annual influenza vaccine safety monitoring.
Received 7 October 2002; accepted 25 November 2002; electronically published 5 March 2003.
Financial support: University of British Columbia Centre for Disease Control.